tafasitamab
Selected indexed studies
- Tafasitamab. (, 2012) [PMID:38985926]
- Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study. (Haematologica, 2024) [PMID:37646664]
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. (Lancet Oncol, 2020) [PMID:32511983]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tafasitamab. (2012) pubmed
- Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study. (2024) pubmed
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. (2020) pubmed
- Tafasitamab. (2006) pubmed
- Tafasitamab: First Approval. (2020) pubmed
- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. (2026) pubmed
- Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. (2021) pubmed
- Tafasitamab-cxix. (2020) pubmed
- RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. (2023) pubmed
- Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study. (2023) pubmed